search/
neurologyAsk MangoMD
Welcome

Medicine, together

India's clinical fellowship & knowledge hub
FeedDashboardFocus

Your daily brief

8 items
01
Cardiology2d
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
Despite lowering Lp(a), this drug did not cut heart attack or stroke risk—so don't start checking Lp(a) routinely yet.
02
Endocrinology3d
Smoking raises death risk by 55% in people with diabetes, global experts call for active quit treatment
For your diabetic patients who smoke, actively offer cessation—this consensus quantifies a 55% higher death risk and urges routine intervention.
03
Neurology3d
Nearly Half of Dementia Cases May Be Preventable-Here's What the Research Says So Far.
Targeting modifiable risks like hypertension, hearing loss, and smoking could cut dementia incidence nearly in half—screen and counsel at-risk patients.
04
General Surgery4d
Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.
Shows a xenograft can safely bridge to human transplant without sensitisation—offering a viable path for patients awaiting deceased-donor kidneys.
05
Oncology5d
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
For fit AML patients, this trial compares the non-intensive azacitidine-venetoclax against standard induction—potentially changing first-line options and toxicity trade-offs.
06
Oncology5d
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
If you treat advanced NSCLC, this oral RAS(ON) inhibitor may offer a new option for the ~30% with RAS mutations after prior therapy.
07
General Medicine6d
Drug-resistant infections kill more, cost more: ICMR study
For clinicians, this quantifies the mortality and cost burden of resistant Gram-negative infections, urging early culture-guided therapy and stewardship.
08
Oncology4d
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
For relapsed/refractory myeloma patients who have exhausted standard options, etentamig offers a new bispecific with improved PFS—consider as a later-line therapy.
The daily brief, by email

What's new in medicine and AI, before rounds

New evidence, approvals, and where AI is actually reaching the clinic — chosen for practising doctors in India. About five minutes, every morning at 7am.

We'll email a link to confirm — that's how we know it's really you. One click to unsubscribe, any time. We never share your address.

Worth a closer look

General Medicineguideline

FSSAI to tighten scrutiny, weighs central ban on non-dairy paneer

A central ban would curb adulterated analogue paneer in your patients' diets, reducing risks from undeclared fats and additives.
ETHealthworld1d
General Medicineguideline

Delhi HC backs NMC: Fragmented foreign medical degrees not enough for FMGE eligibility

If you supervise or train FMGE aspirants, this ruling tightens verification—fragmented foreign training won't qualify, affecting recruitment and credential checks.
ETHealthworld2d
General Surgerytrial

Liposuction versus conservative therapy for patients with lipoedema in Germany: a multicentre, randomised controlled clinical trial.

If liposuction proves superior, you can offer women with lipoedema a durable option beyond compression and manual drainage, which often fail to relieve pain.
PubMed — NEJM / Lancet / BMJ / Annals2d
Paediatricsapproval

FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products

Ensures neonatal intensive care units can keep stocking starter PN for premature infants during potential shortages, preventing treatment delays.
FDA — Press Announcements2d
Oncologyapproval

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

For oncologists in India, this approval signals a new option for advanced breast cancer, but check local availability and cost before changing practice.
FDA — Press Announcements2d
Neurologyapproval

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

First therapy for Alexander disease—an ASO targeting GFAP—offers a disease-modifying option for a fatal leukodystrophy, though availability in India remains unclear.
Fierce Biotech3d